CSF3 and sweet syndrome: This case emphasizes that for individuals with underlying diseases such as bone marrow lesions or abnormal immune function, when Sweet’s syndrome occurs after the use of G-CSF, in addition to considering the factor of drug induction, more attention should be paid to its potential as an early warning signal of hematological malignancies.